FDA approved a generic drug, leading to a market rally, involving Amphastar Pharmaceuticals.
2 reports, 1 independent
Updated Aug 12
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved a generic drug, leading to a market rally, involving Amphastar Pharmaceuticals.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Amphastar Pharmaceuticals is moving forward with product candidate AMP 002, which is currently under FDA review, alongside plans to expand its domestic manufacturing capacity.Sub-event
FDA granted approval for a generic drug, spurring a market rally.1 source
Keep exploring
The entities involved
- FDA
-
Amphastar Pharmaceuticals
publicly traded American pharmaceutical company
Nothing else this week.
Related events
- FDA approves generic drug market entry, with Lanreotide challenging Somatuline Depot market share.
- FDA approval enables commercial opportunity involving CBRE Group.
- FDA approval clears the path for drug market entry, driving future regulatory focus for major pharmaceutical companies.
- The FDA is monitoring drug industry practices and pricing, utilizing studies published by JAMA.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
Coverage
Newest first; wire copies grouped- StockStoryWhy Is Amphastar Pharmaceuticals (AMPH) Stock Soaring Today Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 10.4% in the morning session after the company announced it
- StockStoryFortrea, Azenta, Bio-Techne, 10x Genomics, and Amphastar Pharmaceuticals Stocks Trade Up, What You Need To Know A number of stocks jumped in the afternoon session after a new trade agreement between